Generic DuoNeb Availability
Last updated on May 7, 2025.
DuoNeb is a brand name of , approved by the FDA in the following formulation(s):
DUONEB (albuterol sulfate; ipratropium bromide - solution;inhalation)
-
Manufacturer: NORVIUM BIOSCIENCE
Approval date: March 21, 2001
Strength(s): EQ 0.083% BASE;0.017% (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of DuoNeb. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
More about DuoNeb (albuterol / ipratropium)
- DuoNeb consumer information
- Check interactions
- Compare alternatives
- Reviews (4)
- Side effects
- Dosage information
- During pregnancy
- Drug class: bronchodilator combinations
Related treatment guides
Related/similar drugs
Symbicort
Symbicort (budesonide and formoterol) is used to prevent bronchospasm in people with asthma or ...
Ventolin HFA
Ventolin HFA (albuterol) is used to treat or prevent breathing problems in patients who have asthma ...
Breztri Aerosphere
Breztri (budesonide/glycopyrrolate/formoterol fumarate) is a combination inhaler used for the ...
Ventolin
Ventolin is used for asthma, acute, asthma, maintenance, bronchiectasis, bronchospasm prophylaxis ...
Breo Ellipta
Breo Ellipta (fluticasone and vilanterol) is used to prevent airflow obstruction or bronchospasm in ...
Spiriva
Spiriva (tiotropium) is used to prevent bronchospasm in people with bronchitis, emphysema, or COPD ...
Anoro Ellipta
Anoro (umeclidinium and vilanterol inhalation powder) is used to treat chronic obstructive ...
Xopenex
Xopenex is a short-acting bronchodilator used to treat or prevent bronchospasm in asthma and other ...
Stiolto Respimat
Stiolto Respimat (tiotropium bromide and olodaterol) is used to treat COPD. Includes Stiolto ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.